Sakar Healthcare Ltd
Sakar Healthcare Ltd Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
3 of 5 strong
The short version
Oncology revenue expected to double from INR100 crores in FY26 to INR200 crores in FY27, and triple to around INR280-300 crores in FY28. Oncology business expected to nearly double revenue from INR100 crores to INR200 crores in FY27 and triple to INR280-300 crores in FY28.
From Sakar Healthcare Ltd's Q1 FY27 earnings-call transcript · updated 3 Sept 2026.
Revenue & Sales Performance
- Oncology revenue expected to double from INR100 crores in FY26 to INR200 crores in FY27, and triple to around INR280-300 crores in FY28.
- Total oncology revenue potential estimated between INR800 crores to INR1,000 crores within 3-4 years.
- Export business contribution expected to rise to about 30% of oncology sales by FY27, driven by marketing authorizations and site variations.
- Domestic CMO business for oncology targeted to double from approximately INR35 crores in FY26 to about INR70 crores in FY27.
- Non-oncology (CDMO and API) business expected to grow steadily at 7-8% CAGR in line with generic market trends.
- Increasing marketing authorizations (current 16, targeting over 100 by FY28) to drive export growth and revenue doubling each year.
- Backward integration with API and CEP approvals to improve margins and support scalable growth.
Profitability & Margins
See what Sakar Healthcare Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- No further capex or capital investment is planned for the next few years as the current facility supports ongoing and upcoming product development.
- The existing setup is sufficient to commercialize 6-7 additional molecules coming off-patent in the next couple of years without requiring expansion.
- Focus remains on expanding dossier submissions, regulatory approvals, and commercialization within the current infrastructure.
- Investment is primarily directed towards backward integration of APIs with CEP certifications to improve margins and operational robustness.
- R&D and product development are internally funded, with no current plans for external government or agency grants.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Sakar Healthcare Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Sakar Healthcare currently has over 250 dossiers registered or in pipeline for export markets, indicating a strong orderbook for oncology products.
- 178 dossiers have already been submitted to regulatory agencies worldwide, with 16 marketing authorizations (MAs) approved so far.
- Another 50-plus dossiers are expected to be submitted within the next 1-2 quarters, with an addition of around 25-30 dossiers every quarter going forward.
- The company has completed more than 50-60 export agreements/contracts overseas and 15 contracts in the domestic market.
- They are targeting to double the dossier approvals this financial year to over 100 and aim for 100+ approvals next financial year, which will significantly boost the orderbook.
- The current quarterly run-rate is INR70-75 crores, with expectations to reach INR90 crores in upcoming quarters due to increased export contributions.
Sakar Healthcare Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹71 Cr, net profit ₹11 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Sakar Healthcare Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Novartis India Ltd (Q1 FY27)
Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…
- IOL Chemicals & Pharmaceuticals Ltd (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
- Innova Captab Ltd (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
- Glenmark Pharmaceuticals Ltd (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
Frequently Asked Questions
What were Sakar Healthcare Ltd Q1 FY27 results?
Oncology revenue expected to double from INR100 crores in FY26 to INR200 crores in FY27, and triple to around INR280-300 crores in FY28. Oncology business expected to nearly double revenue from INR100 crores to INR200 crores in FY27 and triple to INR280-300 crores in FY28.
What is Sakar Healthcare Ltd share price analysis?
Sakar Healthcare Ltd currently shows a strong growth signal based on ranking data. The stock trades at a P/E of 54.0 with a market cap of ₹1,948 Cr. Investors should review the full earnings analysis for detailed insights.
Is Sakar Healthcare Ltd planning capital expenditure?
No further capex or capital investment is planned for the next few years as the current facility supports ongoing and upcoming product development.
Keep Sakar Healthcare Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.